AIC
SRPT icon

Ameritas Investment Company’s Sarepta Therapeutics SRPT Stock Holding History

Ameritas Investment Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-300
Closed -$28K – 1434
2020
Q1 		$28K Buy
+300
New +$34.3K ﹤0.01% 896
2019
Q2 		– Sell
-300
Closed -$36K – 788
2019
Q1 		$36K Buy
+300
New +$38.6K 0.01% 476

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameritas Investment Company's SRPT Position: Q2 2020 in Review

Ameritas Investment Company sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 300 shares — an estimated $28K sold.

Ameritas Investment Company first reported a position in SRPT in Q1 2019 and held it in 2 quarters. The position peaked at $36K in Q1 2019. 409 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

  • Ameritas Investment Company reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 300 Sarepta Therapeutics shares in Q2 2020, an estimated $28K.
  • Ameritas Investment Company first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 2 quarters.
  • Ameritas Investment Company's Sarepta Therapeutics position peaked at $36K in Q1 2019.
  • 409 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.